Acura Pharmaceuticals, Inc.
Palatine, US · New York corporation · 2 known investors
Founders & leadership
AW
Albert W. BrzeczkoNamed on SEC filing
GK
George K. RossNamed on SEC filing
JF
James F. EmighNamed on SEC filing
PA
Peter A. ClemensNamed on SEC filing
RB
Robert B. JonesNamed on SEC filing
RS
Robert SeiserNamed on SEC filing
WS
William SkellyNamed on SEC filing
Board
BW
IT
Immanuel ThangarajBoard director
Investors · 2
Reported raises · per SEC filings
Form D private placements$4M disclosed across 1 of 2 rounds · 2017–2024
▶$4MraisedJul 2017 · 1 investors · PharmaceuticalsRule 506(b)
▶$4MraisedJul 2017 · 1 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Albert W. BrzeczkoExecutive Officer
- George K. RossDirector
- James F. EmighExecutive Officer
- Bruce WessonDirector
- Immanuel ThangarajDirector
- Peter A. ClemensExecutive Officer
- Robert B. JonesExecutive Officer, Director
- Robert SeiserExecutive Officer
- William SkellyDirector
- Offering amount
- $4M
- Amount sold
- $4M
- First sale
- Jul 2017
- Incorporated
- Corporation, New York
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
Frequently asked questions
- Who are Acura Pharmaceuticals, Inc.'s investors?
- Acura Pharmaceuticals, Inc.'s investors include Essex Woodlands Healthcare Partners, Galen Partners.
- How much funding has Acura Pharmaceuticals, Inc. raised?
- Acura Pharmaceuticals, Inc. has disclosed $4M raised across 1 of its 2 known rounds.
- Where is Acura Pharmaceuticals, Inc. headquartered?
- Acura Pharmaceuticals, Inc. is headquartered in Palatine, US.